Can Valeant keep its debt-fueled M&A binge going strong enough? That's the question

Serial dealmaker Valeant ($VRX) seems to have bounced back since its failed bid for Allergan ($AGN) in November. The Canadian pharma has since inked two deals and is rumored to have another one in the works. But its heavy debt load has some questioning whether it can deliver on its goal of becoming one of the world's top 5 drugmakers by 2016. More from FiercePharma

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?